Hadrien Chef Bio

Hadrien Chef works closely with many different types of clients in Belgium's thriving tech, pharma and biotech landscape. From start-ups to multinationals, his advice helps client identify how to success and grow as a business. Hadrien is an experienced corporate lawyer who specialises in mergers and acquisitions (M&A), venture capital, public offerings, corporate reorganisations, corporate and security law, and corporate finance. In his role as Partner in Osborne Clarke’s Brussels corporate team, he advises on public and private M&As, and acts for clients on a wide variety of transactional matters and restructurings, including setting-up, financing, reorganising, acquiring, or liquidating business ventures, also providing litigation services in these areas. He furthermore supports clients with ECM, prospectus issuance and market abuse advice or disputes. Hadrien works with clients at the cutting edge of pharma, biotechnology medical diagnostics and medtech. For example, he has been advising OncoDNA, a cancer theranostic company, for several years as their trusted advisor in both M&A and their commercial expansion. Other clients active in biotech, medtech, and medical diagnostics include Sunrise, Kiomed, BioKuris, BioSenic, ImmunXperts, Delphi Genetics, Vesale Pharma, Kitozyme, Gabi Smartcare, Tasso, and BepharBel Manufacturing. While an unquestioned specialist in the field of life sciences, Hadrien has significant expertise in other areas, including technology, media and communications, and transportation and automotive, again regularly advising on M&A transactions, joint ventures and investment schemes. In particular, he works with technology companies active in Belgium and throughout Europe, helping them with strategic partnerships, investments and acquisitions. For example, he has recently advised RTL Group, P&V Assurances, Audiense, Acapela, Bolt, Cream and Fortino on their acquisitions, sale or investments and Sunrise, Merchery, Greentripper and Greenomy on their financing rounds.